Answers are grounded in this paper and cite their sources.
No funding contributed to the writing of this commentary. Both authors are employed by the Cystic Fibrosis Foundation. The Cystic Fibrosis Foundation has entered into therapeutic development award agreements and licensing agreements to assist with the development of CFTR modulators that may result in intellectual property rights, royalties, and other forms of consideration provided to CFF. Some of these agreements are subject to confidentiality restrictions and, thus, CFF cannot comment on them.
No takes yet. Share an insight, caveat, or question.
Bruce C. Marshall (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: